Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026)

Jazz Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• On a quarterly basis, Other Non-Current Assets fell 21.1% year-over-year to $7.1 million in Q1 2026; TTM through Mar 2026 was $7.1 million, a 21.1% decrease from a year earlier, with the FY2025 full-year figure at $99.0 million, up 943.31% from the prior year.
• Other Non-Current Assets declined to $7.1 million in Q1 2026 per JAZZ's latest filing, from $99.0 million in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $99.0 million in Q4 2025 and bottomed at $4.4 million in Q3 2024.
• The 5-year median for Other Non-Current Assets is $8.6 million (2023), against an average of $20.0 million.
• Across the five-year window, Other Non-Current Assets tumbled 88.25% in 2023 and surged 943.31% in 2025, its largest moves.
• Year by year, Other Non-Current Assets stood at $55.1 million in 2022, then tumbled by 88.25% to $6.5 million in 2023, then soared by 46.48% to $9.5 million in 2024, then jumped by 943.31% to $99.0 million in 2025, then plunged by 92.83% to $7.1 million in 2026.
• Per Business Quant, the three latest JAZZ Other Non-Current Assets figures stand at $7.1 million (Q1 2026), $99.0 million (Q4 2025), and $8.0 million (Q3 2025).